Comments

You have commented 375 times on Rantburg.

Your Name

Your e-mail (optional)

Website (optional)

	My Original Nic Pic-a-Nic Sorry. Comments have been closed on this article.
Foto

Submit your comments on this article

Science & Technology

STUDY on Off-label use of Ivermectin and Mebendazole in the treatment of cancer

2026-06-09

[GeorgiaRecord] Recently, The Wellness Company announced a first of its kind human observational study of the off-label use of Ivermectin and Mebendazole in the treatment of cancer was published by the Anticancer Research Journal.

Dr. Peter McCullough, Chief Scientific Officer for The Wellness Company, and one of the authors of the manuscript, praised the results of this groundbreaking analysis. “In this first of its kind human observational analysis, off-label use of Ivermectin+Mebendazole showed a remarkable 84% Clinical Benefit Ratio in the treatment of cancer. These results indicate that the inexpensive and safe off-label applications of these medications could be an important breakthrough in the treatment of cancer.”

The Anticancer Research Journal is a major international oncology journal of the International Institute of Anticancer Research - established in 1995.

Nicolas Hulscher, of the McCullough Foundation, emphasized just how ground-breaking this type of study is, “real world observational studies are incredibly important because they most accurately reflect how Ivermectin+Mebendazole are used in practical applications.”

The publication of this study makes it the largest peer-reviewed human study on the use of Ivermectin + Mebendazole in the treatment of cancer.

84% OF CANCER PATIENTS REPORTED A CLINICAL BENEFIT
In this human observational analysis, off-label use of Ivermectin+Mebendazole showed a remarkable 84% Clinical Benefit Ratio in the treatment of cancer. These results indicate that the inexpensive and safe off-label applications of these medications could be an important breakthrough in the treatment of cancer.

The report analyzed 197 cancer patients who were prescribed ivermectin and mebendazole off label. Participants received compounded oral capsules containing 25 mg of ivermectin and 250 mg of mebendazole. After 6-months, participants reported an 84% Clinical Benefit Ratio. With 48% of participants reporting regression or no evidence of cancer, while 36% reported disease stability. Only 15.6% of participants reported disease progression.

Cancer remains one of the leading causes of death globally, with conventional treatments such as chemotherapy, radiation therapy, and targeted agents frequently limited by significant toxicity, high cost, development of resistance, and variable long-term efficacy.

The experts at The Wellness Company undertook this study because ivermectin and mebendazole have demonstrated highly promising anti-cancer activity in preclinical models. But despite compelling preclinical data and documented safe use in cancer patients, robust clinical evidence evaluating the ivermectin–mebendazole combination in oncology remains limited.

According to Dr. McCullough, “This study reveals an exciting new potential that should expand the consideration of ivermectin and mebendazole for inclusion in the treatment of multiple cancer types. We urgently need a full-fledged scientific investigation into this class of medications and their impact on cancer treatment.”

Posted by:NN2N1

#4 comments); ?>werwer

Posted by: NN2N1 2026-06-09 10:16

#3 comments); ?>werwer

Posted by: Besoeker 2026-06-09 09:09

#2 comments); ?>werwer

Posted by: Warthog 2026-06-09 08:55

#1 comments); ?>werwer

Posted by: NN2N1 2026-06-09 05:53

00:00